Novo Nordisk’s Liraglutide Gets Panel Nod For Weight Management
This article was originally published in The Pink Sheet Daily
Executive Summary
Advisory committee members are generally comfortable with use of the GLP-1 receptor agonist in the first-line setting, suggesting that a second-line treatment restriction in diabetes could be lifted.